Breast cancer rates are sky high and in this month of breast cancer awareness, we see campaigns supporting breast cancer awareness everywhere around us.
Yes, the color pink is in the air, the sports arenas, streets, hospitals, universities, monuments, print media, social media and electronic media; essential every responsible citizen is playing a role in increasing breast cancer awareness in their communities. Be it about sharing information on self-examination for the tumor or supporting the cause by donning a pink ribbon, we know that knowing more about the cancer can help communities at large at fighting out breast cancer.
Breast cancer is estimated to affect 1 in 8 women in the U.S alone any time during their life but what sets it apart from other tumors is the cancer’s good prognosis resulting in excellent survival rates.
Thereby, tumor detection at our early stage plays an essential role in improving survival rates for women who have a breast cancer diagnosis.
However, the efforts for combating breast cancer don’t stop here but they continue to bring relief for women who are already fighting from this disease and have high chances of recurrence. This really is good news for you if you are a cancer survivor or you know of some brave warrior on a quest of defeating breast cancer.
University of Michigan has come forward with a substantial research which will impact the treatment of breast cancer greatly.
Precision medicine, which offers a tailor-made treatment to each individual, finally comes to the rescue of breast cancer patients.
But, how does this really work to help breast cancer patients? Cancer is a life-limiting disease which every patient wants to get rid out before it eats away their body like a termite. In this desperate endeavor of getting the cancer treated, the patients often go for treatments which don’t only carry serious side effects but are not required to treat the patient, in the first place.
For instance, the controversy surrounding chemotherapy is real which leads to serious consequences resulting in deteriorated health of the cancer survivor. To counter the harmful impact, a genetic test has been formulated which looks at 21 genes in the breast cancer patient and evaluates the risk of recurrence.
This, in turn is found to be of great help to reduce the patient’s unnecessary exposure to chemotherapy.
This will also help the oncologists to offer tailor-made treatment to patients based on their genetic makeup so every individual patient gets a treatment which suits them the most.
The researchers surveyed 1,527 women who had received a diagnosis of breast cancer at stage 1 to see if the ’21-gene recurrence score assay test’ was taken to these patients or not and how the test helped them decide the route of their cancer treatment.
Out of the patients who received this test, 87% patients had high cancer recurrence that had to receive chemotherapy, while out of those with low score, 3% went for chemotherapy.
Although more unified efforts are required to make this test more common in clinical set ups, this test is the first step in the right direction to minimize chemotherapy exposure of breast cancer patients who do not need it.
This will lead women to fight off breast cancer once and for all, to continue their life being in the pink of health, again.